Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor and Pharmaceutical Use Therefor
Summary
The USPTO granted patent US12605359B2 to THE KITASATO INSTITUTE on April 21, 2026, covering a low-molecular weight compound that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) functions. The patent protects the compound represented by formula (I), its pharmaceutically acceptable salts and solvates, and medicaments containing the PCSK9 inhibitor for prevention or treatment of PCSK9-related diseases and disorders. The patent contains 5 claims.
What changed
The USPTO issued patent US12605359B2 to THE KITASATO INSTITUTE, granting exclusive rights to a low-molecular weight PCSK9 inhibitor compound and pharmaceutical compositions containing it. The patent covers therapeutic applications for prevention or treatment of symptoms, diseases, or disorders related to PCSK9 functions. The patent was applied for under Application No. 17795812 and contains 5 claims.
Pharmaceutical manufacturers and drug developers working on PCSK9-targeted therapeutics should be aware that THE KITASATO INSTITUTE now holds enforceable patent rights in this space. Companies pursuing similar PCSK9 inhibitor compounds or therapeutic applications should review freedom-to-operate positions and consider potential licensing discussions. The patent's enforceability period extends to the standard 20-year term from the filing date.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor
Grant US12605359B2 Kind: B2 Apr 21, 2026
Assignee
THE KITASATO INSTITUTE
Inventors
Hiroshi Tomoda, Tohru Nagamitsu, Satoshi Omura, Paolo Parini, Osman Ahmed, Matteo Pedrelli, Camilla Pramfalk, Mats Eriksson
Abstract
A low-molecular weight compound having an activity of inhibiting the functions of proprotein convertase subtilisin/kexin type 9 (PCSK9), a PCSK9 inhibitor containing a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active component, and a medicament containing the PCSK9 inhibitor as an active component for use in prevention or treatment of one or more symptoms, diseases, or disorders, related to the functions of PCSK9.
CPC Classifications
A61K 31/366 A61P 1/16 A61P 3/06
Filing Date
2021-01-27
Application No.
17795812
Claims
5
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.